UA104589C2 - Каннабиноиды в комбинации с неканнабиноидными химиотерапевтическими агентами, например смре или алкилирующими агентами - Google Patents

Каннабиноиды в комбинации с неканнабиноидными химиотерапевтическими агентами, например смре или алкилирующими агентами

Info

Publication number
UA104589C2
UA104589C2 UAA201015910A UAA201015910A UA104589C2 UA 104589 C2 UA104589 C2 UA 104589C2 UA A201015910 A UAA201015910 A UA A201015910A UA A201015910 A UAA201015910 A UA A201015910A UA 104589 C2 UA104589 C2 UA 104589C2
Authority
UA
Ukraine
Prior art keywords
cannabinoids
combination
serm
agents
cannabinoid chemotherapeutic
Prior art date
Application number
UAA201015910A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дієз Гільєрмо Веласко
Пастор Мануель Гузман
Мар Лоренте
Софія Торрес
Original Assignee
Джидаблю Фарма Лімітед
Оцука Фармасьютікал Ко. Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джидаблю Фарма Лімітед, Оцука Фармасьютікал Ко. Лімітед filed Critical Джидаблю Фарма Лімітед
Publication of UA104589C2 publication Critical patent/UA104589C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретение относится к сфере медицины и фармацевтики и касается комбинации каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) в форме растительного экстракта в соотношении от 5:1 до 1:5 вместе с неканнабиноидным химиотерапевтическим агентом, который представляет собой селективный модулятор эстрогенового рецептора или алкилирующий агент, для применения в лечении опухоли мозга, более конкретно глиомы, еще более конкретно мультиформной глиобластомы (МФГ).
UAA201015910A 2008-06-04 2009-06-04 Каннабиноиды в комбинации с неканнабиноидными химиотерапевтическими агентами, например смре или алкилирующими агентами UA104589C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0810203.0A GB2460672B (en) 2008-06-04 2008-06-04 Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
PCT/GB2009/050620 WO2009147438A1 (en) 2008-06-04 2009-06-04 Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)

Publications (1)

Publication Number Publication Date
UA104589C2 true UA104589C2 (ru) 2014-02-25

Family

ID=39638156

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201015910A UA104589C2 (ru) 2008-06-04 2009-06-04 Каннабиноиды в комбинации с неканнабиноидными химиотерапевтическими агентами, например смре или алкилирующими агентами

Country Status (24)

Country Link
US (3) US20110086113A1 (ru)
EP (2) EP2320881B1 (ru)
JP (2) JP5674649B2 (ru)
KR (1) KR20110053944A (ru)
CN (1) CN102083426B (ru)
AR (1) AR072002A1 (ru)
AU (1) AU2009254935B2 (ru)
BR (1) BRPI0911384A8 (ru)
CA (1) CA2726257C (ru)
CO (1) CO6341551A2 (ru)
DK (1) DK2320881T3 (ru)
ES (2) ES2887084T3 (ru)
GB (2) GB2460672B (ru)
IL (1) IL209739A0 (ru)
MX (1) MX2010013036A (ru)
MY (1) MY156264A (ru)
NZ (1) NZ589373A (ru)
PT (1) PT2320881T (ru)
RU (1) RU2543034C2 (ru)
SG (1) SG191643A1 (ru)
TW (1) TWI469777B (ru)
UA (1) UA104589C2 (ru)
WO (1) WO2009147438A1 (ru)
ZA (1) ZA201008558B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2554592B (en) * 2010-03-12 2018-07-11 Gw Pharma Ltd A glioma treatment Comprising Temozolomide with a mixture of THA and CBD ar a ration of 1:1
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
FI3122426T3 (fi) 2014-03-28 2023-03-31 Univ Duke Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
US20170189373A1 (en) * 2015-05-15 2017-07-06 Andrew Hospodor Terpene Control in Scaleable Cannabinoid Medicinal Formulations
CA3187317A1 (en) 2015-10-27 2017-05-04 Jay Pharma, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
CA3006182A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CN111629724A (zh) * 2017-09-02 2020-09-04 科学控股公司 四氢大麻酚调节剂
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
US20220362168A1 (en) * 2019-08-09 2022-11-17 Jay Pharma Inc. Administration regimes of cannabinoids in combination with chemotherapeutics against cancer
US20220288007A1 (en) * 2019-08-19 2022-09-15 Diverse Biotech, Inc. Platinum Complex Anti-Neoplastic Agents Comprising a Cannabinoid Ligand

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
ES2164584A1 (es) * 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
RU2166948C1 (ru) * 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения глиом с эпилептическим синдромом
CA2422320A1 (en) * 2000-09-14 2002-03-21 The Regents Of The University Of California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) * 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US7285687B2 (en) * 2002-04-25 2007-10-23 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
EP1907444B1 (en) * 2005-04-01 2009-08-19 Intezyne Technologies Incorporated Polymeric micelles for drug delivery
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
AU2006247526A1 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
KR100675281B1 (ko) * 2005-09-05 2007-01-29 삼성전자주식회사 디커플링 캐패시터를 갖는 반도체 소자 및 그 제조방법
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
UA71391U (ru) * 2012-01-05 2012-07-10 Харьковский Государственный Университет Питания И Торговли Способ получения сыра плавленого пастообразного

Also Published As

Publication number Publication date
BRPI0911384A8 (pt) 2018-04-03
GB2475183A (en) 2011-05-11
EP3213748B1 (en) 2021-08-18
WO2009147438A1 (en) 2009-12-10
EP2320881A1 (en) 2011-05-18
TWI469777B (zh) 2015-01-21
GB0810203D0 (en) 2008-07-09
PT2320881T (pt) 2017-12-22
MY156264A (en) 2016-01-29
JP2015057411A (ja) 2015-03-26
DK2320881T3 (en) 2018-01-02
US20190099492A1 (en) 2019-04-04
US20210069333A1 (en) 2021-03-11
ES2887084T3 (es) 2021-12-21
CO6341551A2 (es) 2011-11-21
US20110086113A1 (en) 2011-04-14
AR072002A1 (es) 2010-07-28
IL209739A0 (en) 2011-02-28
JP5674649B2 (ja) 2015-02-25
AU2009254935B2 (en) 2015-03-19
TW201002316A (en) 2010-01-16
AU2009254935A1 (en) 2009-12-10
ZA201008558B (en) 2014-11-26
GB2460672A (en) 2009-12-09
JP2011522028A (ja) 2011-07-28
CA2726257C (en) 2016-09-13
BRPI0911384A2 (pt) 2015-12-29
EP2320881B1 (en) 2017-09-20
NZ589373A (en) 2013-05-31
EP3213748A1 (en) 2017-09-06
CN102083426A (zh) 2011-06-01
KR20110053944A (ko) 2011-05-24
CN102083426B (zh) 2015-05-13
MX2010013036A (es) 2011-02-18
CA2726257A1 (en) 2009-12-10
GB201101072D0 (en) 2011-03-09
GB2475183B (en) 2011-11-23
ES2653200T3 (es) 2018-02-06
GB2460672B (en) 2012-01-04
SG191643A1 (en) 2013-07-31
RU2543034C2 (ru) 2015-02-27
RU2010154672A (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
MY156264A (en) Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g serm or alkylating agents)
UA104426C2 (ru) Противоопухолевые эффекты комбинаций каннабиноидных соединений
IN2012DN02018A (ru)
PH12016502066A1 (en) Methods of treating bladder cancer
UA109271C2 (ru) Комбинация фитоканабиноидов и темозоламида для лечения глиомы
NZ587706A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
MY166014A (en) Combination therapy methods for treating proliferative diseases
IL219992A0 (en) Combination therapy for treating cancer and dianostic assays for use therein
CR20120202A (es) Métodos y composiciones para tratar cáncer
NZ749217A (en) Androgen receptor modulator and uses thereof
GB201020860D0 (en) Disulfiram formulation and uses thereof
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2134855A4 (en) PROGNOSIS, DIAGNOSIS AND USES IN THE TREATMENT OF FANCI CANCER AND FANCI MODULATION AGENTS
PL2532680T3 (pl) Kompozycja medyczna do leczenia raka i/lub zapobiegania
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2165715A4 (en) THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER
ZA200907245B (en) Phthalazinone derivatives and their use as medicament to treat cancer
MX343773B (es) Uso de ligandos sigma en dolor por cancer de huesos.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
GB2484050A (en) Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer
EP2963125A4 (en) METHOD FOR TESTING A MICRO-RNA, MEDICAMENT FOR THE TREATMENT OF CANCER AND MEDICAL COMPOSITION THEREOF FOR CANCER THERAPY
EP2419111A4 (en) CANCER THERAPY SENSITIZING AGENTS, METHODS OF USE, AND METHODS OF IDENTIFYING THESE AGENTS